Download presentation
Presentation is loading. Please wait.
Published byAndrea Moody Modified over 9 years ago
1
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary
2
AB 1/03 Circulatory Support PCI / Acute MI Cardiogenic shock Cardiac Surgery High risk CABG Weaning Bridge to transplant Chronic Heart Failure ?
3
AB 1/03 Circulatory Support Balloon Counterpulsation Results & Evidence Guidelines Assist Devices: Developments
4
AB 1/03 Intra-Aortic Balloon Pump Inflatable 32-40 cc balloon Triggered to inflate with helium immediately after aortic valve closure Triggered to deflate with opening of the aortic valve
5
AB 1/03 Intra-Aortic Balloon Pump
6
AB 1/03 Intra-Aortic Balloon Pump Decreases Afterload Increases Diastolic Aortic Pressure Increases Coronary Flow Velocity Reduces Myocardial Oxygen Demand
7
AB 1/03 Circulatory Support Balloon Counterpulsation Results & Evidence Guidelines Assist Devices: Developments
8
AB 1/03 Intra-Aortic Balloon Pump Current Practice Results from the Benchmark Registry Ferguson et al. J Am Coll Cardiol 2001; 38:1456
9
AB 1/03 Benchmark Registry June 96-August 2000 203 Hospitals (90%US) 16909 patient case records Verified by external audit Ferguson et al. J Am Coll Cardiol 2001; 38:1456
10
AB 1/03 Benchmark Registry: Indication Hemodynamic support during/after catheterisation 20.6% Cardiogenic shock18.8% Weaning from CP bypass16.1% Preoperative use in high risk pts13% Refractory unstable angina12.3% Ferguson et al. J Am Coll Cardiol 2001; 38:1456
11
AB 1/03 Benchmark Registry: Complications Major: Limb ischemia, severe bleeding, balloon leak, death due to IABP2.6% In –hospital mortality21.2% Failed IABP insertion2.3% Increased risk for major complications: –Women –Low BSA –Older patients –PVD Ferguson et al. J Am Coll Cardiol 2001; 38:1456
12
AB 1/03 IABP Evidence A prospective randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute MI treated with primary angioplasty Stone et al. J Am Coll Cardiol 1997
13
AB 1/03 IABP in direct angioplasty Hypothesis: routine use of IABP after primary PCI reduces infarct related artery reocclusion Multicentre, randomised trial High risk patients randomised to 36 to 48hrs IABP or standard care Stone et al. J Am Coll Cardiol 1997
14
AB 1/03 IABP in direct angioplasty High risk Age>70yrs 3 vessel disease LVEF<45% SVG occlusion Persistent malignant arrhythmia Subotpimal result* Stone et al. J Am Coll Cardiol 1997 *Stents 1.3%
15
AB 1/03 IABP in direct angioplasty N:1100 Angio for MI N: 908 randomised N: 437 high risk IABP 211no IABP 226 Established 86%Crossover 13% Stone et al. J Am Coll Cardiol 1997
16
AB 1/03 IABP in direct angioplasty Stone et al. J Am Coll Cardiol 1997
17
AB 1/03 IABP in direct angioplasty Stone et al. J Am Coll Cardiol 1997 No difference in hemorrhagic complications or vascular complications Significant difference in stroke ‘This finding may be due to chance ….. One intracranial hemorrhage developed after a postinfarction patient was hit in the head with a shovel while robbing the hospital nursery ‘ Complications
18
AB 1/03 IABP Evidence A randomized comparison of intraaortic balloon pumping after primary coronary angioplasty in high risk patients with acute MI treated Van ‘t Hoft 1999, Eur Heart J
19
AB 1/03 IABP Evidence Van ‘t Hoft 1999, Eur Heart J N 238 ov er 3.5 years 118 IABP120 no IABP Primary endpoint: Death, Re-MI, stroke, EF<30% at 6 months FU -> 26% vs 26% No difference in EF 8% major complications in IABP group
20
AB 1/03 IABP Evidence: SHOCK Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction A report from the SHOCK trial registry Sanborn et al. J Am Coll Cardiol 2000;
21
AB 1/03 IABP Evidence: SHOCK Sanborn et al. J Am Coll Cardiol 2000; 36:1123 Background: National registry of MI suggests lower mortality in pts treated with thrombolysis followed by IABP (49%) compared with thrombolysis alone (69%) GUSTO trend towards better outcome
22
AB 1/03 SHOCK Registry Sanborn et al. J Am Coll Cardiol 2000; 36:1123 N: 856 patients with cardiogenic shock in acute MI 36 participating centres Treatment: No thrombolysis / no IABP 33% IABP only33% Thrombolysis only15% Thrombolysis and IABP19%
23
AB 1/03 p<.0001 p=.005 SHOCK Registry: Mortality Sanborn et al. J Am Coll Cardiol 2000; 36:1123
24
AB 1/03 SHOCK Result Sanborn et al. J Am Coll Cardiol 2000; 36:1123 IABP vs. no IABP mortality after adjustement for revascularisation p=0.313 Use of IABP with or without thrombolysis improves survival in pts with cardiogenic shock because of the higher rate of attempted revascularisation in the IABP group
25
AB 1/03 Circulatory Support Balloon Counterpulsation Results & Evidence Guidelines Assist Devices: Developments
26
AB 1/03 Guidelines “Emergency high risk PCI such as direct PCI for acute MI can usually be performed without IABP or CPS. … However, it should be noted that in patients with borderline hemodynamics, ongoing ischemia, or cardiogenic shock, insertion of an intra-aortic balloon just prior to coronary instrumentation has been associated with improved outcomes. Furthermore it is reasonable to obtain vascular access in the contralateral femoral artery prior to the procedure in patients in whom the risk of hemodynamic compromise is high…” AHA/ACC Guidelines for PCI, Circulation 2001
27
AB 1/03 Guidelines Recommendations for the use of IABP in the treatment of AMI Class I Cardiogenic shock not quickly reversed with pharmacological therapy as a stabilising measure for angiography and prompt revascularisation Acute MR or VSD – as a stabilising therapy for angio and repair/ revascularisation Recurrent intractable ventricular arrhythmias with hemodynamic instability Refractory post –MI angina as a bridge to revascularisation AHA/ACC Guidelines for AMI, JACC 1996, Web update 1999
28
AB 1/03 Guidelines Recommendations for the use of IABP in the treatment of AMI Class IIa Signs of hemodynamic instability, poor LV, or persistent ischemia in patients with large areas of myocardium at risk Class IIb Following successful angioplasty to prevent reocclusion Large areas at risk w/o active ischemia AHA/ACC Guidelines for AMI, JACC 1996
29
AB 1/03 Summary IABP Intra-Aortic Balloon Pump is an excellent tool for the management of hemodynamically unstable patients especially in the setting of acute MI
30
AB 1/03 Circulatory Support Balloon Counterpulsation Results & Evidence Guidelines Assist Devices: Developments
31
AB 1/03 Assist Devices: Indications Cardiogenic shock in AMI Postsurgical myocardial dysfunction Acute cardiac failure from myocarditis Decompensated chronic heart failure
32
AB 1/03 Assist Devices: Goals Bridge to transplantation Bridge to recovery Alternative to heart transplantation Delgado et al Circulation 2002;106:2046
33
AB 1/03 Devices Extracorporeal Assist (e.g.Thoratec/Abiomed) Implantable LV assist devices (Heartmate) Axial Flow pumps Totally implantable LVAD (Lion Heart) Total Artificial Heart (ABIOCOR) Delgado et al Circulation 2002;106:2046
34
AB 1/03 Heartmate TM
35
AB 1/03 Heartmate
36
AB 1/03 Heartmate N:129 Quality of life
37
AB 1/03 Abiocor TM
38
AB 1/03 Abiocor TM
39
AB 1/03 Abiocor TM
40
AB 1/03 Abiocor TM
41
AB 1/03 Assist Devices Progress in technology promises new surgical treatment options for end stage heart failure Our surgical colleagues should be pleased to finally have hearts that we won’t fix with percutaneous intervention
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.